Two years ago, when Johnson & Johnson announced it was spinning off its consumer brands including Tylenol, Band-Aid, Motrin, ...

Kenvue faces challenges with declining sales, cash flow risks, and high leverage. Read here for more analysis on KVUE stock.

Band-Aid and Tylenol maker Kenvue has fired its CEO Thibaut Mongon, the consumer health company said on Monday, laying what ...

Kenvue stock surged Monday after the company — known for brands like Tylenol — announced sweeping changes, including naming a ...

Kenvue (KVUE), the company behind Tylenol and Neutrogena, announced that Thibaut Mongon had left the company, naming Kirk ...

The consumer health company also disclosed its CEO’s departure, following its CFO replacement earlier this year, and appointed an interim chief executive. Preliminary second-quarter 2025 results show ...

CEO and board member Thibaut Mongon has stepped down, it said on Monday and named company director Kirk Perry as interim chief executive. The company, which was spun off from Johnson & Johnson ...

NEW YORK/FRANKFURT (Reuters) -Activist shareholders are poised to push harder for corporate changes in the coming months, finding fresh confidence to launch campaigns as the pace of dealmaking picks ...

Kenvue (NYSE: KVUE) stock rose 5.4% after the consumer health company’s CEO and board member Thibaut Mongon stepped down, its ...

Starboard has been one of the industry's busiest activist investors, pushing for changes at several companies in the last one year, including Band-Aid maker Kenvue, drugmaker Pfizer and design ...

Kenvue's CEO and board member Thibaut Mongon has stepped down, it said on Monday, in the second big executive change at the ...

Activist shareholders are poised to push harder for corporate changes in the coming months, finding fresh confidence to launch campaigns as the pace of dealmaking picks up again.